Exhibit 10.2


 


SECURITIES PURCHASE AGREEMENT


 


This SECURITIES PURCHASE
AGREEMENT (the “Agreement”), dated as of _____, 20__, is made by and among Acurx Pharmaceuticals, Inc., a
corporation organized under the laws of Delaware (the “Company”), and the investors listed on the Schedule of Buyers
attached hereto (individually, a “Buyer” and collectively, the “Buyers”).


 


WHEREAS:


 


A.           The Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rules 504
and/or 506, as applicable, of Regulation D (“Regulation D”) as promulgated by the United States Securities and
Exchange Commission (the “SEC”) under the 1933 Act.


 


B.            Each
Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that aggregate
number of shares of common stock of the Company (the “Shares”) set forth opposite such Buyer’s name in column
(3) on the Schedule of Buyers (which aggregate amount of Shares for all Buyers together shall collectively be referred to herein
as the “Common Stock”) and (ii) warrants, in substantially the form attached hereto as Exhibit A (the
 “Warrants”), to acquire up to that number of additional Shares set forth opposite such Buyer’s name in column
(4) of the Schedule of Buyers (as converted, collectively, the “Warrant Interests”). The total amount of
Shares and Warrants being issued by the Company hereunder is up to a maximum aggregate offering amount of $______ (with an option exercisable
by the Company, in its sole discretion, for up to an additional $______).


 


C.            The
Company and each Buyer are executing an Investor Rights Agreement, dated the date hereof, in the form attached hereto as Exhibit B
(the “Investor Rights Agreement”), pursuant to which the Company agrees to provide certain registration rights with
respect to the Common Stock, and the Warrant Interests under the 1933 Act and the rules and regulations promulgated thereunder, and
applicable state securities laws.


 


D.            The
Company and each Buyer desire that each such Buyer join and become a party to the Investor Rights Agreement.


 


E.            The
Shares, the Warrants and the Warrant Interests collectively are referred to herein as the “Securities”.


 


NOW, THEREFORE, the
Company and each Buyer hereby agree as follows:


 


1.             PURCHASE
AND SALE OF COMMON STOCK AND WARRANTS.


 


(a)            Purchase
of Common Stock and Warrants. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, at each
closing of the transaction contemplated hereby (each, a “Closing”), the Company shall issue and sell to each Buyer,
and each Buyer severally, but not jointly, agrees to purchase from the Company on the Closing Date (as defined below), (A) the number
of Shares as is set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers, along with (B) Warrants
to acquire up to that number of Warrant Interests as is set forth opposite such Buyer’s name in column (4) on the Schedule
of Buyers. Each Closing shall occur on the Closing Date at the offices of Mintz Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 666 Third
Avenue, New York, New York 10017 or remotely via the electronic exchange of documents and facsimile signatures. The Schedule of Buyers
shall be amended accordingly following each Closing.


 






    


     


    

 


(b)            Purchase
Price. The purchase price for the Shares and related Warrants to be purchased by each Buyer at the Closing shall be the amount set
forth opposite such Buyer’s name in column (5) of the Schedule of Buyers (the “Purchase Price”) which shall
be equal to the amount of $_____ per Share and the related Warrants.


 


(c)            Closing
Date. The date and time of the initial Closing hereunder shall be ____ [a.m./p.m.], New York City Time, on the date first written
above. Each Buyer acknowledges and agrees that the Company may, in its sole discretion, conduct subsequent and multiple Closings for such
amounts and Shares and Warrants as the Company may, in its sole discretion, determine, up a maximum amount of $______ worth of Securities.
The date of each Closing hereunder shall be a “Closing Date.”


 


(d)            Form of
Payment. On each Closing Date, (i) each Buyer shall pay its respective Purchase Price to the Company for the Shares and Warrants
to be issued and sold to such Buyer at the Closing by wire transfer of immediately available funds in accordance with the Company’s
written wire instructions and (ii) the Company shall deliver to each Buyer (A) one or more certificates, evidencing the number
of Shares such Buyer is purchasing as is set forth opposite such Buyer’s name in column (3) of the Schedule of Buyers, and
(B) a Warrant pursuant to which such Buyer shall have the right to acquire such number of Warrant Interests as is set forth opposite
such Buyer’s name in column (4) of the Schedule of Buyers in all cases duly executed on behalf of the Company and registered
in the name of such Buyer or its designee.


 


(e)            Joinder.
Each Buyer, by their execution of a joinder agreement to be delivered to the Company as of the Closing Date on which such Buyer purchases
Common Stock and Warrants, agrees to become a party to the Investor Rights Agreement. Each Buyer acknowledges receipt of the the Investor
Rights Agreement.


 


2.             BUYER’S
REPRESENTATIONS AND WARRANTIES. Each Buyer, severally and not jointly, represents and
warrants with respect to only itself that, as of the date hereof and as of the applicable Closing Date:


 


(a)            No
Public Sale or Distribution. Such Buyer is (i) acquiring the Shares and the Warrants and (ii) upon exercise of the Warrants
(other than pursuant to a Cashless Exercise (as defined in the Warrants)) will acquire the Warrant Interests issuable upon exercise thereof
for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant
to sales registered or exempted under the 1933 Act and such Buyer does not have a present arrangement to effect any distribution of Securities
to or through any person or entity; provided, however, that by making the representations herein, such Buyer does not agree
to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in
accordance with or pursuant to a registration statement or an exemption under the 1933 Act. Such Buyer is acquiring the Securities hereunder
in the ordinary course of its business. Such Buyer does not presently have any agreement or understanding, directly or indirectly, with
any Person (as defined in Section 3(p)) to distribute any of the Securities.


 






    2


     


    

 


(b)            Accredited
Investor Status. Such Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation
D or a “sophisticated” investor as defined in Regulation D or an entity that is a “qualified institutional buyer”
within the meaning of Rule 144A promulgated under the 1933 Act.


 


(c)            Reliance
on Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions from
the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth
and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of such Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of such Buyer to acquire
the Securities.


 


(d)            Information.
Such Buyer and its advisors, if any, have been furnished with material information relating to the business, finances and operations of
the Company and the offer and sale of the Securities which have been requested by such Buyer, including the Company’s ____________,
describing the Company and the transactions contemplated hereby. Such Buyer and its advisors, if any, have been afforded the opportunity
to ask questions of the Company. Such Buyer understands that its investment in the Securities involves a high degree of risk and is able
to afford a complete loss of such investment. Such Buyer has sought such accounting, legal and tax advice as it has considered necessary
to make an informed investment decision with respect to its acquisition of the Securities.


 


(e)            No
Governmental Review. Such Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.


 


(f)            Transfer
or Resale. Such Buyer understands that except as provided in the Investor Rights Agreement: (i) the Securities have not been
and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred
unless (A) subsequently registered thereunder, (B) such Buyer shall have delivered to the Company, an opinion of counsel, in
a form reasonably satisfactory to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned
or transferred pursuant to an exemption from such registration, or (C) such Buyer provides the Company with reasonable assurance
that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or
a successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Securities made in reliance
on Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale
of the Securities under circumstances in which the seller (or the Person) through whom the sale is made) may be deemed to be an underwriter
(as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations
of the SEC thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the Securities under
the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the
foregoing, the Securities may be pledged in connection with a bona fide margin account or other loan or financing arrangement secured
by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder,
and no Buyer effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery
to the Company pursuant to this Agreement or any other Transaction Document (as defined in Section 3(b)), including, without limitation,
this Section 2(f).


 






    3


     


    

 


(g)            Legends.
Such Buyer understands that the certificates or other instruments representing the Shares and the Warrant Interests and, until such time
as the resale of the Shares and the Warrant Interests have been registered under the 1933 Act as contemplated by the Investor Rights Agreement,
the certificates representing the Warrant Interests, except as set forth below, shall bear any legend as required by the “blue sky”
laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer
of such certificates):


 


[NEITHER THE ISSUANCE AND SALE OF THE
SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN][THE SECURITIES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“ACT”), OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE ACT OR (B) AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE
COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.*


 


The legend set forth above shall be removed and
the Company shall issue a certificate without such legend to the holder of the Securities upon which it is stamped if, unless otherwise
required by state securities laws, (i) such Securities are registered for resale under the 1933 Act, (ii) in connection with
a sale, assignment or other transfer, such holder provides the Company with an opinion of counsel reasonably satisfactory to the Company
to the effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements
of the 1933 Act and that such legend is no longer required, or (iii) such holder provides the Company with reasonable assurance that
the Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A without limitation. The Company shall
be responsible for the fees, if any, of its transfer agent associated with such issuance.


 





 



 * Bracketed language to be inserted if applicable.


 






    4


     


    

 


(h)            Validity;
Enforcement. This Agreement and the Investor Rights Agreement have been duly and validly authorized, executed and delivered on behalf
of such Buyer and shall constitute the legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance
with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies.


 


(i)             No
Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the Investor Rights Agreement and the consummation
by such Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents
of such Buyer or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or
instrument to which such Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree
(including federal and state securities laws) applicable to such Buyer, except in the case of clauses (ii) and (iii) above,
for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a
material adverse effect on the ability of such Buyer to perform its obligations hereunder.


 


(j)             Residency.
Such Buyer is a resident of that jurisdiction specified below its address on the Schedule of Buyers.


 


(k)            General
Solicitation. Such Buyer is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television, radio or via the Internet
or presented at any seminar or, to such Buyer’s knowledge, any other general solicitation or general advertisement.


 


(l)             Fees.
Such Buyer shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or broker’s commissions
(other than for Persons engaged by the Company) relating to or arising out of the transactions contemplated hereby. Such Buyer shall pay,
and hold the Company harmless against, any liability, loss or expense (including, without limitation, reasonable attorney’s fees
and out-of-pocket expenses) arising in connection with any claim relating to any such payment.


 


3.             REPRESENTATIONS
AND WARRANTIES OF THE COMPANY. the Company represents and warrants to each of the Buyers
that, as of the date hereof and as of the applicable Closing Date:


 


(a)            Organization
and Qualification; Subsidiaries. The Company is an entity duly organized and validly existing in good standing under the laws of Delaware
and has the requisite power and authorization to carry on their business as now being conducted. The Company is duly qualified as a foreign
entity to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a
Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on
the business, properties, assets, operations, results of operations or condition (financial or otherwise) of the Company, taken as a whole,
or on the transactions contemplated hereby or on the other Transaction Documents or by the agreements and instruments to be entered into
in connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under the Transaction Documents
(as defined below). The Company has no subsidiaries.


 






    5


     


    

 


(b)            Authorization;
Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under this Agreement,
the Investor Rights Agreement, the Warrants and each of the other agreements entered into by the parties hereto in connection with the
transactions contemplated by this Agreement (collectively, the “Transaction Documents”) and to issue the Securities
in accordance with the terms hereof and thereof. The execution and delivery of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Shares and the
Warrants and the reservation for issuance and the issuance of the Warrant Interests issuable upon exercise of the Warrants have been duly
authorized by the Company’s Board of Directors and no further consent or authorization is required by the Company, its Board of
Directors or its members. This Agreement and the other Transaction Documents have been duly executed and delivered by the Company, and
constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective
terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and
remedies.


 


(c)            Issuance
of Securities. The Common Stock and the Warrants are duly authorized and, upon issuance in accordance with the terms hereof, shall
be validly issued and free from all taxes, liens and charges with respect to the issue thereof and the Common Stock shall be fully paid
and nonassessable with the holders being entitled to all rights accorded to a holder of Shares. As of the Closing Date, the Company shall
have duly authorized and reserved for issuance a number of Common Stock which equals the maximum number of Warrant Interests issuable
upon exercise of the Warrants. The Company shall, so long as any of the Warrants are outstanding, take all action necessary to reserve
and keep available for issuance, solely for the purpose of effecting the exercise of the Warrants, 100% of the number of Shares issuable
upon exercise of the Warrants. Upon exercise in accordance with the Warrants, the Warrant Interests will be validly issued, fully paid
and nonassessable and free from all preemptive or similar rights, taxes, liens and charges with respect to the issue thereof, with the
holders being entitled to all rights accorded to a holder of Shares. The offer and issuance by the Company of the Securities is exempt
from registration under the 1933 Act.


 


(d)            No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares and the Warrants and the
reservation for issuance and issuance of the Warrant Interests) will not (i) result in a violation of the Certificate of Incorporation
(as defined below), the Bylaws, or other constituent documents of the Company or (ii) conflict with, or constitute a default (or
an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any material agreement, indenture or instrument to which the Company is a party.


 






    6


     


    

 


(e)            Consents.
The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental
agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations
under or contemplated by the Transaction Documents, in each case in accordance with the terms hereof or thereof except for filings pursuant
to Regulation D of the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner.
All consents, authorizations, orders, filings and registrations which the Company is required to obtain prior to the Closing Date pursuant
to the preceding sentence have been obtained or effected on or prior to the Closing Date. The Company is unaware of any facts or circumstances
that might prevent the Company from obtaining or effecting any of the registration, application or filings pursuant to the preceding sentence.


 


(f)            Acknowledgment
Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the capacity
of arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and that,
except as set forth on Schedule 3(f), no Buyer is (i) an officer or director of the Company, (ii) an “affiliate”
of the Company or (iii) to the knowledge of the Company, a “beneficial owner” of more than 10% of the Common Stock (as
defined for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “1934 Act”)). The Company
further represents to each Buyer that the Company’s decision to enter into the Transaction Documents has been based solely on the
independent evaluation by the Company and its representatives.


 


(g)            No
General Solicitation. Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf, has engaged in
any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the
Securities.


 


(h)            No
Integrated Offering. None of the Company, its affiliates, or any Person acting on their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of any
of the Securities under the 1933 Act, whether through integration with prior offerings or otherwise. Neither the Company, nor its affiliates
or any Person acting on their behalf have taken any action or steps referred to in the preceding sentence that would require registration
of any of the Securities under the 1933 Act or cause the offering of the Securities to be integrated with other offerings for purposes
of any applicable membership approval provisions.


 


(i)             Dilutive
Effect. The Company acknowledges that its obligation to issue the Warrant Interests upon exercise of the Warrants in accordance with
this Agreement and the Warrants, in each case, is absolute and unconditional regardless of the dilutive effect that such issuance may
have on the ownership interests of other members of the Company.


 






    7


     


    

 


(j)             Application
of Takeover Protections. The Company has not adopted an equity holder rights plan or similar arrangement relating to accumulations
of beneficial ownership of Common Stock or a change in control of the Company.


 


(k)            No
Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred or exists,
or is contemplated to occur, with respect to the Company or its business, properties, prospects, operations or financial condition, that
would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form S-1 filed with
the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced.


 


(l)             Conduct
of Business; Regulatory Permits. The Company is not in violation of any term of its Certificate of Incorporation (the “Certificate
of Incorporation”) or Bylaws. The Company is not in violation of any judgment, decree or order or any statute, ordinance, rule or
regulation applicable to the Company. The Company currently possesses all certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct its business, except where the failure to possess such certificates,
authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and the Company has not received
any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.


 


(m)            Foreign
Corrupt Practices. The Company has not, nor has any director, officer, agent, employee or other Person acting on behalf of the Company,
in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the
U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback
or other unlawful payment to any foreign or domestic government official or employee.


 


(n)            Transactions
With Affiliates. None of the officers, directors or employees of the Company is presently a party to any transaction with the Company
(other than for ordinary course services as employees, officers or directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring
payments to or from any such officer, director or employee or any corporation, partnership, trust or other entity in which any such officer,
director, or employee has a substantial interest or is an officer, director, trustee or partner.


 


(o)            Equity
Capitalization. As of _______, 20__, the Company has an aggregate of _______ shares of common stock issued and outstanding and _____
shares of preferred stock issued and outstanding. All of such outstanding Shares have been, or upon issuance will be, validly issued and
are fully paid and nonassessable. Except as may be set forth in the bylaws of the Company (the “Bylaws”) or this Agreement,
no common stock or preferred stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered
or permitted by the Company. In addition, except as may be set forth in the Bylaws or this Agreement, there are no outstanding options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any common stock or preferred stock of the Company, or contracts, commitments, understandings
or arrangements by which the Company is or may become bound to issue additional common stock or preferred stock or options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into,
or exercisable or exchangeable for, any class of stock of the Company. The Company has furnished or made available to the Buyer upon such
Buyer’s request, true, correct and complete copies of the Company’s Certificate of Incorporation and Bylaws, in each case,
in effect on the date hereof.


 






    8


     


    

 


(p)            Indebtedness
and Other Contracts. The Company (i) has no outstanding Indebtedness (as defined below), (ii) is not in violation of any
term of or in default under any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults
would not result, individually or in the aggregate, in a Material Adverse Effect, or (iii) is not a party to any contract, agreement
or instrument relating to any Indebtedness, the performance of which, in the judgment of the Company’s officers, has or is expected
to have a Material Adverse Effect. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without
duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase
price of property or services, including, without limitation, “capital leases” in accordance with United States generally
accepted accounting principles (other than trade payables entered into in the ordinary course of business), (C) all reimbursement
or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced
by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of
property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement,
or incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even
though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale
of such property), (F) all monetary obligations under any leasing or similar arrangement which, in connection with generally accepted
accounting principles, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness
referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right,
contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property
or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has
not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness
or obligations of others of the kinds referred to in clauses (A) through (G) above; (y) “Contingent Obligation”
means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness, lease,
dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary
effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements
relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with
respect thereto; and (z) “Person” means an individual, a limited liability company, a partnership, a joint venture,
a corporation, a trust, an unincorporated organization and a government or any department or agency thereof.


 






    9


     


    

 


(q)            Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation before any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of the Company’s
officers or directors, whether of a civil or criminal nature or otherwise.


 


(r)             Insurance.
The Company currently has or plans to obtain directors’ and officers’ liability insurance in amounts deemed satisfactory in
connection with the Company’s ongoing business and operations and no other insurance. The Company has not been refused any insurance
coverage sought or applied for.


 


(s)            Intellectual
Property Rights. The Company owns or possesses adequate rights or licenses to use all trademarks, trade names, service marks, service
mark registrations, service names, original works of authorship, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and other intellectual property rights and all applications and registrations therefor (“Intellectual
Property Rights”) necessary to conduct its business as now conducted. The Company does not have any knowledge of any infringement
by the Company of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought, or to the knowledge
of the Company, being threatened, against the Company regarding its Intellectual Property Rights. The Company is not aware of any facts
or circumstances which might give rise to any of the foregoing infringements or claims, actions or proceedings. The Company has taken
reasonable security measures to protect the secrecy, confidentiality and value of all of its Intellectual Property Rights.


 


(t)             Tax
Status. The Company was formed in July 2017 and has filed all material U.S. federal and/or state income or other tax returns,
reports and declarations required to date. There are no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company know of no basis for any such claim.


 


(u)            Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated
or other off balance sheet entity that would be reasonably likely to have a Material Adverse Effect.


 


(v)            Transfer
Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be paid in
connection with the sale and transfer of the Securities to be sold to each Buyer hereunder will be, or will have been, fully paid or provided
for by the Company, and all laws imposing such taxes will be or will have been complied with.


 


(w)            Investment
Company Status. The Company is not, and upon consummation of the sale of the Securities, will not be, an “investment company,”
a company controlled by an “investment company” or an “affiliated person” of, or “promoter” or “principal
underwriter” for, an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended.


 


(x)             U.S.
Real Property Holding Corporation. The Company is not and has never been, a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Buyer’s request.


 






    10


     


    

 


(y)            Bank
Holding Company Act. The Company is not subject to the Bank Holding Company Act of 1956, as amended (the “BHCA”)
and to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve”). The Company does
not own or control, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
The Company does not exercise a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA
and to regulation by the Federal Reserve.


 


(z)             No
Additional Agreements. The Company does not have any agreement or understanding with any Buyer with respect to the transactions contemplated
by the Transaction Documents other than as specified in the Transaction Documents.


 


(aa)           Disclosure.
The Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting transactions in securities
of the Company. With respect to each Buyer severally, all written disclosure provided to such Buyer regarding the Company, its business
and the transactions contemplated hereby, including the Schedules to this Agreement, furnished by or on behalf of the Company are true
and correct and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees
that no Buyer makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those
specifically set forth in Section 2 of this Agreement.


 


4.             COVENANTS.


 


(a)            Best
Efforts. Each party shall use its best efforts timely to satisfy each of the covenants and the conditions to be satisfied by it as
provided in Sections 5, 6 and 7 of this Agreement.


 


(b)            Form D
and Blue Sky. The Company shall make all material filings and reports relating to the offer and sale of the Securities required under
applicable federal securities or “Blue Sky” laws of the states of the United States.


 


(c)            Use
of Proceeds. The Company will use the proceeds from the sale of the Securities for general corporate and for working capital purposes
and not for (i) the repayment of any outstanding Indebtedness of the Company or (ii) the redemption or repurchase of any of
its equity securities.


 


(d)            Fees.
The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or broker’s commissions
(other than for Persons engaged by any Buyer) relating to or arising out of the transactions contemplated hereby. The Company shall pay,
and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorney’s fees
and out-of-pocket expenses) arising in connection with any claim relating to any such payment.


 






    11


     


    

 


(e)            Closing
Documents. On or prior to thirty (30) calendar days after the applicable Closing Date, the Company agrees to deliver, or cause to
be delivered, to each Buyer a complete closing set of the Transaction Documents, Securities and any other document required to be delivered
to any party pursuant to Section 7 hereof or otherwise.


 


5.             REGISTER;
TRANSFER AGENT INSTRUCTIONS. The Company shall maintain at its principal executive offices
(or such other office or agency of the Company as it may designate), a register for the Shares and the Warrants, in which the Company
shall record the name and address of the person in whose name the Shares and the Warrants have been issued (including the name and address
of each transferee), the number of Shares held by such person, the number of Warrant Interests issuable upon exercise of the Warrants
held by such person and the number of Shares held by such person. The Company shall keep the register open and available at all times
during normal business hours for inspection of any Buyer or its legal representatives.


 


6.             CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.


 


The obligation of the Company
hereunder to issue and sell the Shares and the related Warrants to each Buyer at the Closing is subject to the satisfaction, at or before
the applicable Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit
and may be waived by the Company at any time in its sole discretion by providing each Buyer with prior written notice thereof:


 


(a)            Such
Buyer shall have executed each of the Transaction Documents to which it is a party (including a Joinder to the Investor Rights Agreement
or this Agreement, as the case may be) and delivered the same to the Company.


 


(b)            Such
Buyer shall have delivered to the Company the Purchase Price for the Shares and the related Warrants being purchased by such Buyer and
each other Buyer at the Closing by wire transfer of immediately available funds pursuant to the wire instructions provided by the Company
or by check made out in the name of the Company.


 


(c)            The
representations and warranties of such Buyer shall be true and correct in all material respects (except for those representations and
warranties that are qualified by materiality or Material Adverse Effect, which are true and correct in all respects) as of the date when
made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date
which shall be true and correct as of such specified date), and such Buyer shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such
Buyer at or prior to the Closing Date.


 


7.             CONDITIONS
TO EACH BUYER’S OBLIGATION TO PURCHASE.


 


The obligation of each Buyer
hereunder to purchase the Shares and the related Warrants at the Closing is subject to the satisfaction, at or before the applicable Closing
Date, of each of the following conditions, provided that these conditions are for each Buyer’s sole benefit and may be waived by
such Buyer at any time in its sole discretion by providing the Company with prior written notice thereof:


 






    12


     


    

 


(a)            The
Company shall have executed and delivered to such Buyer (i) each of the Transaction Documents and (ii) the Shares and the related
Warrants being purchased by such Buyer at the Closing pursuant to this Agreement.


 


(b)            Such
Buyer shall have received the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., the Company’s outside counsel (“Company
Counsel”), dated as of the Closing Date, as to the due authorization and valid issuance of the Securities (but which shall not
include a “10b-5” opinion) substantially in the form attached as Exhibit C hereto.


 


(c)            The
Company shall have delivered to such Buyer a certificate, executed by a Managing Partner of the Company and dated as of the Closing Date,
certifying as to (i) the resolutions as duly adopted by the Company’s Board of Directors relating to the transactions contemplated
hereby as in effect at the Closing, (ii) the Bylaws and the Certificate of Incorporation, each as in effect at the Closing and (iii) the
matters set forth in Section 7(d), in the form attached hereto as Exhibit D.


 


(d)            The
representations and warranties of the Company shall be true and correct in all material respects (except for those representations and
warranties that are qualified by materiality or Material Adverse Effect, which are true and correct in all respects) as of the date when
made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date
which shall be true and correct as of such specified date) and the Company shall have performed, satisfied and complied in all respects
with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the
Company at or prior to the Closing Date.


 


8.             TERMINATION.
With respect to each Closing, in the event that such Closing shall not have occurred with
respect to a Buyer on or before ten (10) Business Days from the applicable Closing Date due to the Company’s or such Buyer’s
failure to satisfy the conditions set forth in Sections 6 and 7 above (and the nonbreaching party’s failure to waive such unsatisfied
condition(s)), the nonbreaching party shall have the option to terminate this Agreement with respect to such breaching party at the close
of business on such date without liability of any party to any other party.


 


9.             MISCELLANEOUS.


 


(a)            Governing
Law; Jurisdiction; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.


 






    13


     


    

 



 


(b)            Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
other electronic signature delivered by fax or e-mail transmission shall be considered due execution and shall be binding upon the signatory
thereto with the same force and effect as if the signature were an original, not a facsimile signature.


 


(c)            Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.


 


(d)            Severability.
If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest
extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity
of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change,
the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the
provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the
practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations
to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as
possible to that of the prohibited, invalid or unenforceable provision(s).


 


(e)            Entire
Agreement; Amendments. This Agreement and all other Transaction Documents supersede all other prior oral or written agreements between
the Buyers, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement,
the other Transaction Document and the instruments referenced herein and therein contain the entire understanding of the parties with
respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor any
Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be
amended other than by an instrument in writing signed by the Company and the holders of Shares and Warrants representing at least a majority
of the number of the Shares together with the number of Shares underlying the Warrants then held by the Buyers and any of their respective
successors or assigns. No provision hereof may be waived other than by an instrument in writing signed by the party against whom enforcement
is sought.


 






    14 


     


    

 


(f)            Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in
writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) when sent, if sent by electronic
mail during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next
Business Day; or (iii) one Business Day after deposit with an overnight courier service, in each case properly addressed to the party
to receive the same. The addresses and email address for such communications shall be:


 


If to the Company:


 


Acurx Pharmaceuticals, Inc.


_____________


_____________


Telephone: ______________


E-mail: _____________


Attention: _____________


 


with a copy (for informational
purposes only) to:


 


David P. Luci


c/o Acurx Pharmaceuticals, Inc.


_____________


_____________


Telephone: _____________


E-mail: ________________


 


If to a Buyer, to its address and email address
set forth on the Schedule of Buyers or to such other address and/or email address and/or to the attention of such other Person as the
recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change.
Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, or (B) provided
by an overnight courier service shall be rebuttable evidence of personal service, receipt by E-mail or receipt from an overnight courier
service in accordance with clause (i), (ii) or (iii) above, respectively.


 


(g)            Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns,
including any purchasers of the Shares or the Warrants. The Company shall not assign this Agreement or any rights or obligations hereunder
without the prior written consent of the holders of Shares representing at least a majority of the number of the Shares together with
the number of Shares underlying the Warrants then held by the Buyers and any of their respective successors or assigns including by way
of a Change of Control (as defined in the Warrants) (unless the Company is in compliance with the applicable provisions governing Change
of Control set forth in the Warrants). A Buyer may assign some or all of its rights hereunder without the consent of the Company, in which
event such assignee shall be deemed to be a Buyer hereunder with respect to such assigned rights.


 






    15 


     


    

 


(h)            No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.


 


(i)            Survival.
Unless this Agreement is terminated under Section 8, the representations and warranties of the Company and the Buyers contained in
Sections 2 and 3, the agreements and covenants set forth in Sections 4, 5 and 9 shall survive the Closing and the delivery and exercise
of Securities, as applicable, for a period of one (1) year. Each Buyer shall be responsible only for its own representations, warranties,
agreements and covenants hereunder.


 


(j)            Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.


 


(k)            No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party.


 


(l)            Independent
Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under any Transaction Document are several and not joint
with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any other
Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Buyer
pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the Buyers do not so constitute,
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Buyers are in any way acting
in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated
by the Transaction Documents and the Company acknowledges that the Buyers are not acting in concert or as a group with respect to such
obligations or the transactions contemplated by the Transaction Documents. The Company acknowledges and each Buyer confirms that it has
independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors.
Each Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of
this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Buyer to be joined as an additional
party in any proceeding for such purpose.


 


[Signature Page Follows]


 






    16 


     


    

 


IN WITNESS WHEREOF,
each Buyer and the Company have caused its respective signature page to this Securities Purchase Agreement to be duly executed as
of the date first written above.


 


	 	COMPANY:
	 	 
	 	ACURX PHARMACEUTICALS, InC.



 


	 	By:	 
	 	Name:	 
	 	Title:	 





 


[Signature
Page to Securities Purchase Agreement]


 






    


     


    

 


 


IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement to be duly executed
as of the date first written above.


 


	BUYERS:	 
	 	 
	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 




 


Investment Amount: $ ___________________________________


 


No. of Shares: ___________________________________


 


No. of Warrants (50% Warrant coverage): ___________________________________


 


[Signature
Page to Securities Purchase Agreement]


 






     


     


    

 


ACURX WIRE INSTRUCTIONS:


 


Bank Name:


 


Account No.


 


ABA Routing No.:


 


Bank Address:


 


Swift Code (for International Wires Only):


 






     


     


    

 


SCHEDULE OF BUYERS


 


	(1)	(2)	(3)	(4)	(5)
	 	 	 	 	 
	Buyer	Address and

E-Mail Address	Number of 

Shares	Number of

 Warrant 

Interests	Purchase

 Price


 






     


     


    

 


EXHIBITS


 


	Exhibit A	Formof Warrant
	Exhibit B	Formof Investor Rights Agreement
	Exhibit C	Formof Company Counsel Opinion
	Exhibit D	Formof Managing Partner’s Certificate




 






     


     


    

 


Exhibit A


 


Form of Warrant


 


[attached hereto]


 






    Exhibit A 


     


    

 


Exhibit B


 


Form of Investor Rights Agreement


 


[attached hereto]


 






    Exhibit B 


     


    

 


Exhibit C


 


Form of Company Counsel Opinion


 


The following opinions of
Company counsel shall be provided with such terms, provisions and caveats as are customary for opinions of like nature:


 


1.            Based
solely on a certificate of good standing issued by the Secretary of State of the State of Delaware, the Company is validly existing as
a limited liability company in good standing under the laws of State of Delaware.


 


2.            The
Company has full right, power and authority to execute and deliver the Transaction Documents and to perform its obligations thereunder,
and all action required to be taken for the due and proper authorization, execution and delivery of the Transaction Documents and consummation
of the transactions contemplated by the Transaction Documents have been duly and validly taken.


 


3.            The
Shares issued to the Buyers have been duly and validly authorized, and when issued and delivered against payment therefor as provided
in the Securities Purchase Agreement, will be validly issued, fully paid and non-assessable.


 


4.            When
issued, the Warrants will constitute valid and binding obligations of the Company to issue and sell, upon exercise thereof and payment
of the respective exercise prices therefor, the number of Shares called for thereby in accordance with the terms thereof and such Warrants
are enforceable against the Company in accordance with their respective terms.


 






    Exhibit C 


     


    

 


Exhibit D


 


Form of Officers’ Certificate


 


Pursuant to the terms of that
certain Securities Purchase Agreement (the “Agreement”), dated _____, 20___ between Acurx Pharmaceuticals, Inc., a corporation
organized under the laws of Delaware (the “Company”), and the Buyers signatory thereof, the undersigned, on behalf of the
Company, hereby certifies by and on behalf of the Company to the Buyers as follows. All capitalized terms used but not defined herein
as have the meanings ascribed to such terms in the Agreement.


 


1.            The
undersigned is a duly appointed and acting Managing Partner of the Company as of the date hereof.


 


2.            A
true, complete and correct copy of the Company’s Bylaws, dated _______, 20__, is attached hereto as Exhibit A (as amended from
time to time, the “Bylaws”). No amendment or other document relating to or affecting the Bylaws has been undertaken since
the date referred to above, and no action has been taken by the Company or members, directors or officers in contemplation of any such
amendment as of the date hereof.


 


3.            A
true, complete and correct copy of the Company’s Certificate of Incorporation, dated _____, 20__, and in full force and effect as
of the date hereof, is attached hereto as Exhibit B (the “Certificate of Incorporation”). No amendment or other document
relating to or affecting the Certificate of Incorporation has been filed with the Secretary of State of the State of Delaware since the
date referred to above, and no action has been taken by the Company or members, directors or officers in contemplation of any such amendment
as of the date hereof.


 


4.            A
true, complete and correct copy of the of resolutions duly and validly adopted by the Board of Directors of the Company relating to the
transactions contemplated by the Agreement at meetings or upon written consent are attached hereto as Exhibit C, which resolutions
have not been suspended or modified in any manner and are in full force and effect as of the date hereof.


 


5.            The
representations and warranties of the Company set forth in the Agreement are true and correct in all material respects as of the date
when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific
date which shall be true and correct as of such specified date).


 


6.            The
Company has performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction
Documents to be performed, satisfied or complied with by the Company at or prior to the Closing Date


 


IN WITNESS WHEREOF, this Managing
Partner’s Certificate has been executed on this ______ day of _____, 20___.


 


		 




 






    Exhibit D 


     


    

 


SCHEDULES


 


Schedule 3(f) – Officers, Directors, Affiliates and 10%
Beneficial Owners